###### What is already known on this topic

-   Gastrointestinal toxicity in association with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids in adults is well documented.

-   There are only a few studies describing the association between gastrointestinal toxicity and NSAID use in children.

###### What this study adds

-   Our study confirms a threefold increased risk of upper gastrointestinal complications (UGIC) associated with either NSAID or oral corticosteroid use.

-   A twofold increased risk of UGIC was estimated for paracetamol and antibiotics.

Introduction {#s1}
============

Mucosal damage to the gastrointestinal tract may lead to a wide spectrum of disorders, from asymptomatic minimal lesions, to severe, potentially fatal, complications.[@R1] Upper gastrointestinal complications (UGICs) such as bleeding are often associated with drug use, especially non-steroidal anti-inflammatory drugs (NSAIDs), oral steroids and oral anticoagulants.[@R2] [@R3]

NSAIDs inhibit the cyclooxygenase enzymes catalysing the production of prostaglandins and thromboxane, with consequent reduced release of gastric mucus, inhibition of bicarbonate production and alteration of local microcirculation.[@R4] Steroids can also enhance gastrin secretion and induce parietal cell hyperplasia with increased acid production.[@R5]

In adults, a small number of studies have specifically examined the association between corticosteroids and gastrointestinal toxicity[@R6; @R7; @R8] and there is an extensive body of literature on gastrointestinal complications related to drug consumption, but few studies have focused on children.[@R5] [@R9; @R10; @R11; @R12; @R13]

Since 1999 active surveillance of the role of drugs and vaccines in the occurrence of specific clinical conditions responsible for the hospitalisation of paediatric patients has been conducted in Italy. This surveillance is useful for highlighting or confirming adverse effects associated with drug and vaccine use in children.[@R14; @R15; @R16; @R17]

In the present article we focus on the occurrence of hospitalisation for UGIC in association with drugs frequently used in the paediatric population, with particular emphasis on antipyretics/analgesics, steroids and antibiotics.

Methods {#s2}
=======

Study population {#s2a}
----------------

The study population consists of all children admitted through the emergency departments (ED) of eight Italian paediatric hospitals in Genoa, Turin, Padua, Florence, Rome (two hospitals), Naples and Palermo between 1 November 1999 and 30 November 2010. Children were enrolled regardless of drug and vaccine use, if they had the following conditions: endoscopically confirmed UGIC (or clinical haematemesis and melena); neurological disorders; non-infectious muco-cutaneous diseases and vasculitis; or thrombocytopenia (platelet count \<100 000/µl). Children with concomitant diagnoses of cancer or immunodeficiency and age less than 1 month were excluded.

Information on the reason for hospital admission was derived from the ED records, and the final diagnosis was retrieved from the clinical records after discharge. UGIC cases comprise all children whose reason for admission included haematemesis/melena and children who had received an endoscopy during hospitalisation and were discharged with a diagnosis of gastroduodenal lesion. The following conditions were defined as gastroduodenal lesions on endoscopy: gastric and/or duodenal ulcer, and gastric and/or duodenal erosions (with or without bleeding).

Parents were interviewed, using a structured questionnaire, during the hospital admission of their child. All medicines administered in the previous 3 weeks and all vaccines received in the previous 12 weeks were noted. Information on drug use, including indication, dose, duration of treatment, prescriber (physician or self-medication) and other personal data (age, gender, weight, height, chronic diseases, parents' education) was also collected.

Data analysis {#s2b}
-------------

ORs of clinically defined (haematemesis and melena) or endoscopically confirmed UGIC associated with drug use were estimated according to a case--control study design. Drug exposure to specific drugs or drug categories in children admitted with UGIC (cases) was compared to exposure in children admitted for neurological disorders (controls). This control group was chosen because drug exposure in children hospitalised for neurological disorders accurately reflects drug exposure in the population from which UGIC cases were derived.

Pre-existing chronic diseases were divided into six categories: allergies, gastrointestinal diseases (gastroesophageal reflux, coeliac disease, ulcerative colitis), haematological disorders, recurrent infections, neurological problems and birth defects. Indications for drug use were classified into nine groups: allergy, asthma, pain or headache, fever, gastrointestinal diseases, otitis, upper respiratory tract infections (URTI), prophylaxis and other indications. The use of oral steroids was categorised as appropriate or not, according to the approved indications; we considered as appropriate prescriptions for asthma and allergy, while all prescriptions for other indications (eg, fever, cough, otitis, pharyngitis) were classified as inappropriate.

Categorical variables, presented as numbers and percentages, were compared using the χ² test, while continuous variables, reported as median (range), were evaluated using the Mann--Whitney U test. All tests were two sided and significance was set at p\<0.05.

To estimate the adjusted ORs and related 95% CIs, we used the multivariate logistic regression model. ORs were adjusted for age, clinical centre, calendar year, presence of chronic diseases and concomitant use of any other drug. Year of inclusion in the study and chronic diseases did not modify the estimates and, thus, were not included in the final logistic model. Statistical analysis was performed using SPSS V.17.0 (SPSS, Chicago, Illinois, USA).

Organisation and ethics {#s2c}
-----------------------

The protocol of the study was approved by the ethics committee of each clinical centre. Informed consent for the use of data for research purposes was obtained before parents were interviewed. The study was coordinated by the National Centre of Epidemiology of the National Institute of Health.

Results {#s3}
=======

A total of 486 children hospitalised for UGIC and 1930 for neurological disorders were enrolled in the study. Of the children hospitalised for UGIC, 324 (66.6%) were admitted for haematemesis, 31 (6.4%) for melena, and 29 (6.0%) for both haematemesis and melena. The remaining 102 children (21.0%) who were admitted for symptoms compatible with gastroduodenal lesions (other than haematemesis/melena), such as abdominal pain and vomiting, underwent endoscopy during hospitalisation and were discharged with a diagnosis of UGIC. An endoscopy was performed in 248 (51%) of the 486 UGIC cases.

The most frequent diagnoses in the 1930 children included in the control group were afebrile convulsions (822, 43%), disturbances of consciousness (such as syncope, faintness, dizziness, somnolence) (530, 27%), peripheral neuropathy (78, 4%) and extrapyramidal symptoms (65, 3%).

The majority of cases (302 children, 62.1%) were admitted to Santobono Hospital (Naples). The main characteristics of cases and controls are summarised in [table 1](#ARCHDISCHILD2012302100TB1){ref-type="table"}. Males were equally represented in both groups, and cases were 5 months younger than controls (p=0.01). However, age did not have a confounding effect when taken into account in the logistic model. Seventy-five of the 486 cases (15.4%) had concomitant chronic diseases versus 265 of the 1930 controls (13.7%) (p=0.37).

###### 

Characteristics of cases (upper gastrointestinal complications) and controls (neurological disorders)

                                               Cases (N=486)   \%     Controls (N=1930)   \%     p Value
  -------------------------------------------- --------------- ------ ------------------- ------ ---------
  Median age, months (25th--75th percentile)   41 (15--71)            46 (11--115)               0.01
  Male                                         274             56.4   1002                51.9   0.08
  Median LoS, days (25th--75th percentile)     3 (2--5)               3 (2--6)                   0.69
  Chronic diseases                             75              15.4   265                 13.7   0.37
   Allergy                                     47              9.7    168                 8.7    0.98
   Gastrointestinal disease                    12              2.5    21                  1.1    0.06
   Haematological disorders                    4               0.8    7                   0.4    0.42
   Recurrent infections                        3               0.6    12                  0.6    0.90
   Neurological problems                       8               1.6    40                  2.1    0.43
   Birth defects                               10              2.1    41                  2.1    0.78
  Drug exposure (at least one)                 353             72.6   1042                54.0   \<0.001
  Indication for use of drugs\*                                                                  
   URTI                                        141             39.9   259                 24.9   \<0.001
   Fever                                       56              15.9   97                  9.3    \<0.001
   Asthma                                      13              3.7    15                  1.4    0.001
   Allergy                                     --              --     19                  1.8    

\*The percentage was calculated on drug exposure.

LoS, length of stay; URTI, upper respiratory tract infection.

Chronic gastrointestinal diseases were uncommon, although more frequent in cases than in controls (2.5% vs 1.1%; p=0.06). The presence of such conditions was an independent risk factor for UGIC manifestations with an adjusted OR of 2.3 (95% CI 1.1 to 4.9). However, after adjustment for the personal history of pre-existing gastrointestinal diseases, no confounding effect was found on the estimates. The number of children who had received at least one drug within the 3 weeks preceding the hospital admission was 353 among cases and 1042 among controls (73% vs 54%; p\<0.001). The mean number of drugs per child was 1.7 among cases and 1.1 among controls (p\<0.001). Approximately 17% of these drugs were consumed without medical advice in both groups. The drugs reported in the personal history were those most frequently prescribed in the paediatric population in Italy, that is, antibiotics, paracetamol, NSAIDs and steroids.

Duration of use was quite short and similar for all study drugs. The median duration for NSAID administration was 3 days in cases and 2 days in controls (p=0.41). One child (4 years old) admitted with haematemesis had been treated for 80 days with indomethacin and ibuprofen for arthritis. The median duration of use for steroids was 3 days in cases and 4 days in controls (p=0.16). The indication was reported in 79 of the 87 steroid users (91%); in 17 children (21.5%) it was an approved indication (eg, asthma, urticaria).

An increased risk of UGIC was found for the use of NSAIDs, paracetamol, corticosteroids and antibiotics. The adjusted OR among NSAID users was 2.9 (95% CI 2.1 to 4.0). The risk estimates of individual NSAIDs and paracetamol presented largely overlapping CIs ([table 2](#ARCHDISCHILD2012302100TB2){ref-type="table"}).

###### 

ORs and CIs of upper gastrointestinal complications in association with drugs\*

  Drugs                         Cases (N=486)   Controls (N=1930)   Adjusted OR† (95% CI)
  ----------------------------- --------------- ------------------- -----------------------
  Antibiotics                   135             242                 2.3 (1.8 to 3.1)
  Amoxicillin+clavulanic acid   44              77                  2.3 (1.5 to 3.5)
  Claritromicin                 17              30                  2.0 (1.0 to 3.8)
  Amoxicillin                   16              30                  1.8 (0.9 to 3.4)
  Cefaclor                      14              24                  1.7 (0.8 to 3.5)
  Steroids                      87              140                 1.9 (1.4 to 2.7)
  Oral steroids                 39              30                  2.9 (1.7 to 4.8)
  Inhaled steroids              24              81                  1.0 (0.6 to 1.7)
  Oral+inhaled steroids         20              18                  3.0 (1.5 to 5.9)
  NSAIDs                        81              121                 2.9 (2.1 to 4.0)
  Ibuprofen                     40              51                  3.7 (2.3 to 5.9)
  Niflumic acid                 14              23                  1.6 (0.8 to 3.2)
  Ketoprofen                    12              23                  2.6 (1.2 to 5.6)
  Paracetamol                   119             294                 2.0 (1.5 to 2.6)
  Paracetamol+ibuprofen         16              21                  3.1 (1.5 to 6.2)
  Aspirin                       6               12                  2.5 (0.9 to 7.4)
  Other drugs                   186             746                 0.8 (0.7 to 1.1)
  Total drug use                353             1042                

\*All drugs with at least 10 exposed in the control group.

†Adjusted for age, clinical centre and concomitant use of other drugs.

NSAIDs, non-steroidal anti-inflammatory drugs; UGIC, upper gastrointestinal complications.

On the basis of the number of children who visited the ED of the participating centres in the year 2010, we calculate that around 2.1 million children were treated in the participating EDs during the study period. Thus, we can roughly estimate that during the study period around 2.4 per 10 000 children with ED visits were admitted for UGIC.

Discussion {#s4}
==========

In this article we provided evidence of an increased risk of UGICs associated with drug use in the paediatric population.

The proportion of children who had received at least one drug in the 3 weeks preceding hospital admission was higher among cases than among controls. Significantly increased risks were estimated for NSAIDs, steroids and antibiotics. In agreement with our findings, an increased risk for NSAIDs was also observed in a case--crossover study of 177 children with gastrointestinal bleeding.[@R9] The adjusted OR for NSAIDs reached 8.2 (95% CI 2.6 to 26.0), with one third of cases attributable to exposure to NSAIDs administered at analgesic or antipyretic doses.[@R9] However, as underlined by the authors, the study has several limitations and the estimated risks appear higher than those observed in adults,[@R2] since the findings may have been influenced by the limited dataset and a recall bias could not be excluded.[@R9]

Among NSAIDs, ibuprofen was the most commonly used drug. Although ibuprofen is safe in most children,[@R18] the association between gastrointestinal bleeding and ibuprofen use is well known in both adults[@R2] and children.[@R10] We estimated an increased risk of UGIC associated with ibuprofen (adjusted OR 3.7, 95% CI 2.3 to 5.9). It has to be noted that our estimate is included in the large CI of the case--crossover study[@R9] and overlaps with findings reported in adults (a twofold to fourfold increase in relative risks).[@R2] It is assumed that gastrointestinal bleeding is associated with chronic use of NSAIDs.[@R19] However, in our study the mean duration of ibuprofen use in cases was 4 days, so UGIC may occur even during a short course therapy. We confirm the lower level of gastrotoxicity, in comparison with NSAIDs, of paracetamol, the most widely used drug in the paediatric population in Italy.

Steroid prescribing was off-label in a large proportion of cases and was mostly used for URTI or fever. This finding underlines the need for educational programmes in Italy to promote the correct use of steroids in children. Notably, the association with UGIC was limited to oral steroid use as no increased risk was observed among users of inhaled steroids.

Although poorly documented in the literature, gastrointestinal adverse reactions, featuring diarrhoea, nausea and abdominal pain, related to antibiotic administration, are usually mild and reversible with treatment cessation.[@R20] [@R21] There are very few data on the upper gastrointestinal toxicity of antibiotics. Immune -mediated thrombocytopenia is often implicated in bleeding mechanisms associated with antibiotics, in particular β-lactams.[@R22] In our study, however, children hospitalised for UGIC did not have a concomitant diagnosis of thrombocytopenia. The reason for an increased risk of UGIC among antibiotic users, after taking into account the effect of age and concomitant use of other drugs, remains unclear.[@R11] [@R22] [@R23]

Our study has several potential limitations. Cases were significantly younger than controls; however, the risk estimates did not change after age was taken into account in the logistic model. An endoscopy was performed only in half of the children diagnosed with UGIC; however, all cases without endoscopic confirmation had haematemesis or melena at admission. The risk estimates did not change when the analysis was restricted to children who underwent endoscopy.

As in other case--control studies, the possibility of a recall bias cannot be excluded. However, such a bias cannot explain the observed risk estimates since the ascertainment of exposure was based on the same procedure in cases and controls (interviewing parents during their child\'s hospitalisation). Children hospitalised for neurological problems are a suitable control group for patients with UGICs. Both cases and controls were admitted through EDs for an acute condition and, consequently, drug use preceding symptoms causing hospitalisation should not differ between cases and controls.

Pre-existing chronic conditions were unlikely to have influenced the results, since the proportions of children with chronic conditions were similar in the two groups. However, the small sample size of some subgroups may have limited our ability to draw definitive conclusions regarding some specific drugs.

Our study indicates that UGIC is a rare event (486 children hospitalised in just over 11 years). Although, given the case--control design, we could not calculate incidence, the number of UGIC patients admitted through EDs can be roughly estimated as 2.4 per 10 000 children with ED visits. Published incidence data are limited to the paediatric intensive care unit population,[@R24] which cannot be compared with children who develop an UGIC as outpatients. Our study suggests that the absolute risk of UGIC is low, nevertheless it remains to be determined if all prescriptions were really necessary. The appropriate use of drugs in children should be promoted in order to prevent the occurrence of serious adverse events.
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